What does GHRP-2 do? Benefits and evidence
A peptide that releases growth hormone and can increase hunger.
Also called: Pralmorelin, KP-102, GPA-748.
Growth hormone secretagogues (ghrelin receptor) · Ghrelin receptor agonist and growth hormone secretagogue.
GHRP-2 raises growth hormone and can increase hunger. Japan uses pralmorelin for supervised GH testing. Human studies mostly measured hormone responses, not lasting muscle or recovery benefits. Cortisol, prolactin and blood sugar can change. Long-term wellness use and online product quality remain poorly studied.
- In small controlled studies, it increased hunger and how much people ate. (Studied in a trial)
- In a study of adults, a supervised one-time IV test helped tell severe growth hormone deficiency apart from normal. (Studied in a trial)
- In a small clinic study, a mix including it raised IGF-1, but muscle gain and fat loss were not measured well. (Studied in a trial)
Uses in the sources
- Studied for GH stimulation testing; pralmorelin has a Japanese diagnostic approval, not an FDA/EMA dose label. (Studied in a trial) (source)
- SC infusion increased food intake in small, controlled studies of lean and obese adults. (Studied in a trial) (source)
- A clinician-published combination raised IGF-1; muscle gain and fat loss were not measured adequately. (Clinician-published) (source)
Related to GHRP-2
- Ipamorelin: An experimental peptide that triggers growth hormone release.
- MK-677 (ibutamoren): This experimental oral drug raises growth hormone and IGF-1; risks include high blood sugar and swelling.
- GHRP-6: A peptide studied in growth hormone tests and an experimental stroke combination.
- Hexarelin: A peptide that releases growth hormone; repeated use can weaken the response.
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- Sermorelin: An experimental short-acting peptide that triggers growth hormone release, with limited evidence of adult benefits.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Find product information about medicines, Medicines and Healthcare products Regulatory Agency · MHRA · 2026
- Peptide products, Therapeutic Goods Administration · TGA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- GENOTROPIN® (somatropin) for injection, for subcutaneous use, FDA · 2025
- 注射用GHRP科研100, PMDA · 2025
- October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee, FDA · 2024
- Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
- Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline., Molitch ME et al. · The Journal of clinical endocrinology and metabolism · 2011
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.